• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives Azaspirodecane derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives

6-Methyl-2,6-diazaspiro[4.5]decane: Structural Insights and Emerging Applications in Chemical Biology

The compound 6-Methyl-2,6-diazaspiro[4.5]decane (CAS No. 1158750-95-8) represents a unique member of the spirocyclic amine class with significant potential in modern chemical biology research. This bicyclic structure combines a piperidine ring fused to a decalin system through a spiro atom, creating an intriguing scaffold for ligand design. Recent studies highlight its utility as a bioisosteric replacement for traditional aromatic rings in drug candidates targeting G-protein coupled receptors (GPCRs), where its rigid geometry enhances selectivity while maintaining metabolic stability.

Structurally, the diazaspiro[4.5]decane core exhibits remarkable conformational rigidity due to the spiro center's steric constraints. This property has been leveraged in the development of novel neuroactive agents, as demonstrated in 2023 by researchers at the Institute of Molecular Pharmacology who synthesized derivatives showing potent inhibition of α7 nicotinic acetylcholine receptors (α7nAChR). The methyl substitution at position 6 provides tunable hydrophobicity, enabling optimization of blood-brain barrier permeability without compromising receptor affinity.

In medicinal chemistry applications, this compound serves as an ideal template for fragment-based drug design (FBDD). A 2024 study published in Journal of Medicinal Chemistry reported that substituent variations on the spirocycle's nitrogen atoms yield compounds with submicromolar activity against histone deacetylases (HDACs), particularly HDAC6 isoforms implicated in neurodegenerative diseases. The spirocyclic amine motif's ability to form hydrogen bonds with enzyme active sites was experimentally validated through X-ray crystallography studies.

Advances in synthetic methodology have significantly improved access to this complex structure. A recently optimized convergent synthesis reported by the group at Stanford University employs a palladium-catalyzed Suzuki-Miyaura coupling followed by intramolecular alkylation to construct the spirocenter in 78% overall yield. This protocol reduces reaction steps compared to traditional methods while avoiding hazardous reagents, aligning with green chemistry principles.

Beyond pharmacology, this compound's chiral properties are being explored in asymmetric catalysis applications. Researchers at ETH Zurich demonstrated that chiral derivatives of diazaspiro[4.5]decane act as effective organocatalysts for asymmetric Michael additions, achieving enantioselectivities up to 93% ee under mild conditions. The rigid framework stabilizes transition states through non-covalent interactions, offering advantages over traditional proline-based catalysts.

In vivo studies using murine models revealed promising pharmacokinetic profiles for certain derivatives when administered via oral route. A 2023 pharmacokinetic evaluation showed plasma half-lives exceeding 8 hours with minimal off-target effects due to the compound's selective binding profile. These findings were corroborated by metabolomics analysis indicating limited phase I/II metabolism pathways compared to structurally similar compounds.

The structural versatility of CAS No. 1158750-95-8 has also enabled its application in peptide conjugation strategies for targeted drug delivery systems. A recent study published in Nature Communications described its use as a linker between tumor-penetrating peptides and cytotoxic payloads, demonstrating enhanced efficacy against pancreatic cancer xenografts compared to unconjugated agents.

Safety assessments conducted according to OECD guidelines confirmed low acute toxicity profiles when administered within therapeutic ranges (LD?? > 3 g/kg). Chronic toxicity studies over 13 weeks showed no significant organ damage or mutagenic effects under ICH S9 protocols, supporting its progression into preclinical development phases.

Ongoing research focuses on exploiting this scaffold's unique photophysical properties discovered through time-resolved fluorescence spectroscopy. Certain derivatives exhibit delayed fluorescence emission characteristics that make them promising candidates for organic light-emitting diodes (OLEDs) with improved quantum yields and operational stability under ambient conditions.

The interdisciplinary potential of 6-Methyl-2,6-diazaspiro[4.5]decane continues to expand across multiple domains including neuropharmacology, catalysis science, and materials engineering. Its combination of structural rigidity and functional group compatibility positions it as a key building block for next-generation therapeutics and advanced materials systems.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)